Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here

ICV 2018: 95.39
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2018.7(1): 1357-1365
DOI: https://doi.org/10.20546/ijcmas.2018.701.165


Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients after Treatment with Sofosbuvir and Daclatasvir
Nashwa A. Abu Khadr1, Hanan H. Nouh2, Nesrine F. Hanafi1, Sara L. Asser1 and Yousra A. Hussain1*
1Department of Microbiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2Department of Internal Medicine, Gastroenterology unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt
*Corresponding author
Abstract:

This study is a cross-sectional study aimed to assess the rate of occurrence of secondary occult hepatitis C virus (HCV) infection in patients treated with the combination of sofosbuvir and daclatasvir. This study included 40 patients whose serum turned negative for HCV ribonucleic acid (HCV RNA) via real time polymerase chain reaction (RT-PCR) after 3 months of the treatment. Blood samples on EDTA were collected from the patients to detect HCV RNA in peripheral blood mononuclear cells (PBMCs). At the end of the study there were 30 PBMCs HCV RNA negative patients and 10 PBMCs HCV RNA positive patients. Our data revealed the occurrence of secondary occult HCV infection in about 25% of HCV patients treated with the combination of sofosbuvir and daclatasvir.


Keywords: Occult HCV, Peripheral blood mononuclear cells, Sofosbuvir, Daclatasvir, Direct acting antiviral drugs
Download this article as Download

How to cite this article:

Nashwa A. Abu Khadr, Hanan H. Nouh, Nesrine F. Hanafi, Sara L. Asser and Yousra A. Hussain. 2018. Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients after Treatment with Sofosbuvir and Daclatasvir.Int.J.Curr.Microbiol.App.Sci. 7(1): 1357-1365. doi: https://doi.org/10.20546/ijcmas.2018.701.165